Progenics Pharmaceuticals Inc. (PGNX) Shares Bought by Los Angeles Capital Management & Equity Research Inc.
Los Angeles Capital Management & Equity Research Inc. increased its position in Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) by 457.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 88,980 shares of the biotechnology company’s stock after acquiring an additional 73,010 shares during the period. Los Angeles Capital Management & Equity Research Inc. owned about 0.13% of Progenics Pharmaceuticals worth $655,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of PGNX. Piedmont Investment Advisors LLC bought a new stake in Progenics Pharmaceuticals during the second quarter valued at about $103,000. Numeric Investors LLC bought a new stake in Progenics Pharmaceuticals during the second quarter valued at about $2,877,000. Royce & Associates LP grew its holdings in Progenics Pharmaceuticals by 7.7% during the second quarter. Royce & Associates LP now owns 1,346,374 shares of the biotechnology company’s stock valued at $9,142,000 after purchasing an additional 95,700 shares during the period. New York State Common Retirement Fund grew its holdings in Progenics Pharmaceuticals by 11.0% during the second quarter. New York State Common Retirement Fund now owns 239,525 shares of the biotechnology company’s stock valued at $1,626,000 after purchasing an additional 23,723 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in Progenics Pharmaceuticals by 8.7% during the second quarter. Principal Financial Group Inc. now owns 594,849 shares of the biotechnology company’s stock valued at $4,039,000 after purchasing an additional 47,647 shares during the period. 84.84% of the stock is owned by institutional investors.
Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) traded down $0.15 during trading on Friday, hitting $5.63. The stock had a trading volume of 249,684 shares, compared to its average volume of 1,078,765. Progenics Pharmaceuticals Inc. has a fifty-two week low of $4.60 and a fifty-two week high of $11.72. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.80.
Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.22) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. The business had revenue of $2.70 million for the quarter, compared to the consensus estimate of $3.58 million. Progenics Pharmaceuticals had a negative return on equity of 67.61% and a negative net margin of 445.81%. The business’s revenue was down 95.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.52 earnings per share. equities research analysts anticipate that Progenics Pharmaceuticals Inc. will post -0.92 EPS for the current fiscal year.
Several analysts have issued reports on the company. ValuEngine lowered Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Cantor Fitzgerald set a $15.00 price objective on Progenics Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Needham & Company LLC restated a “strong-buy” rating and issued a $14.00 price objective on shares of Progenics Pharmaceuticals in a research report on Friday, September 1st. Zacks Investment Research downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. Finally, Aegis restated a “buy” rating and issued a $14.00 price objective on shares of Progenics Pharmaceuticals in a research report on Tuesday, August 22nd. Three equities research analysts have rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $13.75.
Progenics Pharmaceuticals Profile
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals Inc. (NASDAQ:PGNX).
Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.